University Hospital Essen (Westdeutsches Tumorzentrum) | Cancer Care

The Westdeutsches Tumorzentrum is University Hospital Essen’s cancer centre, rather than a separate standalone hospital. Its development is rooted in the university hospital’s integration of patient care, medical education and research. It brings cancer-related departments together around diagnosis-specific pathways and multidisciplinary decision-making.

The centre operates within a large university hospital environment, where oncology care can draw on specialised surgery, transplant medicine, diagnostic services and other medical disciplines. This matters for patients whose cancer or existing health conditions require input beyond a single oncology specialty. It does not mean that every service is needed for every patient.

German Cancer Society certification is a relevant quality marker for its oncology services. Certification concerns defined organisational and clinical standards; patients should check the current certification relevant to their particular cancer programme. It should not be interpreted as a ranking or a guarantee of an individual outcome.

WTZ is particularly associated with complex cancer care, including sarcoma and melanoma programmes, liver transplantation and hepatobiliary surgery, and a large stem cell transplant unit. Its trial activity also makes research an important part of the centre’s role, although most treatment decisions still depend on established clinical evidence and individual circumstances.

Liver cancer care can require coordination between liver specialists, oncologists, interventional teams and hepatobiliary surgeons. The hospital’s surgical and transplant services are relevant to selected patients, but transplantation is not appropriate for every liver tumour. Assessment depends on tumour type and extent, liver function and transplant criteria. Lung cancer care similarly requires accurate staging and tissue diagnosis, with biomarker testing where indicated.

Sarcoma and rare cancer programmes are important because uncommon tumours can be difficult to classify and may need specialist pathology review before treatment. Melanoma is another notable programme, with systemic treatment choices depending on disease stage, molecular findings and previous therapy. Patients should ask whether their exact tumour subtype is routinely managed by the relevant team.

Blood cancer services cover diseases requiring haematology expertise, with stem cell transplantation available for selected indications. The presence of a large transplant unit is relevant to complex treatment planning, but eligibility depends on the disease, response to previous treatment, general health and, where applicable, donor availability.

Surgery and radiation therapy form part of the centre’s treatment options. Their role varies from potentially curative treatment to local disease control or symptom relief. A multidisciplinary review can help establish whether an operation, radiation, systemic therapy or a combination is appropriate, and in what sequence.

Immunotherapy and targeted therapy are available within the oncology treatment portfolio. Neither is suitable for all cancers. Selection may depend on the tumour diagnosis, biomarkers, treatment history, organ function and relevant approvals. Patients should request the clinical rationale for a proposed medicine rather than assuming that a newer treatment is necessarily preferable.

Precision oncology uses molecular and other diagnostic information to guide treatment decisions. Testing may identify an established targeted treatment or suggest a clinical trial, but it can also find no actionable result. A molecular finding alone does not establish that a drug will work or that access and funding are available.

Transplantation requires separate, detailed assessment. Liver transplantation is restricted to selected clinical situations and involves allocation requirements; international referral does not itself establish eligibility. Stem cell transplantation may involve substantial treatment risks and prolonged monitoring. For either procedure, patients need clear explanations of alternatives, expected benefits, complications and the practical requirements for follow-up.

The centre’s reported portfolio of around 400 active oncology clinical trials indicates substantial research activity. This figure is indicative and should be checked directly: study numbers change, and an active study may be following existing participants rather than recruiting new ones. The portfolio should not be read as 400 treatment options for an individual patient.

International patients can ask the relevant disease team to review their records for potentially suitable studies. Screening usually considers the precise diagnosis, stage, molecular findings, previous treatments, general fitness, laboratory results and protocol requirements. Nationality or willingness to travel does not replace clinical eligibility, and some studies require additional on-site testing before enrolment can be confirmed.

Before travelling for a trial, request its identifier, recruitment status, purpose and visit schedule. Ask about randomisation, possible treatment arms, foreseeable risks and alternatives outside the study. Clarify which research procedures are funded and which routine care, travel or accommodation expenses may remain payable.

Start with a concise clinical summary and ask which department should assess the case. Seek written confirmation of whether the initial step is a records review, second opinion, diagnostic visit or planned treatment admission. Avoid non-refundable travel bookings until the hospital has clarified what can be offered and what further information is needed.

Plan for continuity of care between Essen and the treating team at home. Agree who will manage symptoms, prescriptions and urgent complications between visits, and obtain a written treatment summary. For prolonged treatment, discuss whether a caregiver is needed, how long local monitoring may be necessary and which elements of follow-up can safely take place in the home country.

Contact details below come from the hospital's own published international patient information.

Location: Essen, Germany

Email: international@uk-essen.de

Phone: +49 201 723 0

Website: https://www.uk-essen.de

Languages supported: German, English, Russian, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.